For Roche and Genentech, What’s An Agreement Between Friends?
This article was originally published in The Pink Sheet Daily
Executive Summary
Ten-year-old affiliation agreement complicates Roche’s next moves and may give Genentech some leverage, as next steps include what one analyst calls “the nuclear option”